← Back to search

Food and Drug Administration · Department of Health and Human Services

Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

Forecast — not open yet · Opportunity FOR-FD-24-005 · Assistance Listing 93.103

Key facts

Deadline
Forecast — no date yet
Award size
$250K – $500K
Cost share / match
Not required
Who can apply
Tribal organization, Public college or university, Larger business, Tribal government, State government, Anyone (unrestricted), Special district (utility, fire, etc.), County government, Nonprofit without 501(c)(3), Private college or university, Nonprofit with 501(c)(3), School district, City or town government, Small business, Other (see eligibility)
Where
Anywhere in the U.S., including Tennessee

Before you apply: federal grants require an active SAM.gov registration (Unique Entity ID) and a Grants.gov account. Registration is free but can take weeks, so start now, not when the deadline is close. Grant-ready checklist

How this fits you

  • Available in Tennessee (nationwide program)
  • No cost share required
  • Tennessee recipients since 2023: 18

Tell us who you are to see whether you're eligible.

Read the official notice View on Grants.gov

About this grant

The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions. The goal is to develop and validate the in vitro mechanistic methodology to provide an improved understanding of impact of food and acid reducing agents on the absorption for test and reference listed drug (RLD) drug products, taking into consideration their potentially different formulations and manufacturing. The bio predictive in vitro mechanistic methodology is intended to correlate the in vitro observations to in vivo outcomes, help define types of in vivo bioequivalence (BE) studies needed for ASD drug products, and inform regulatory decision-making related to mitigating the risk of potential failure modes for therapeutic equivalence for high-risk generic oral drug products.

Eligibility (from the notice)

Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Who in Tennessee has won this program

18 awards to Tennessee recipients in 5 counties since federal FY2023. Largest shown:

Past Tennessee recipients
RecipientWhereAmountFY
University Of TennesseeKnoxville, Knox County$6.5M2020
Vanderbilt University Medical CenterNashville, Davidson County$2.5M2019
Department Of Agriculture TennesseeNashville, Davidson County$2.4M2020
University Of TennesseeMemphis, Shelby County$2M2017
Department Of Agriculture TennesseeNashville, Davidson County$1.9M2020
Franklin Special School DistrictFranklin, Williamson County$1.8M2025
University Of TennesseeKnoxville, Knox County$1.8M2025
Vanderbilt University Medical CenterNashville, Davidson County$1.6M2022
Department Of Agriculture TennesseeNashville, Davidson County$1.3M2021
Tennessee Department Of HealthNashville, Davidson County$1.3M2020
Department Of Agriculture TennesseeNashville, Davidson County$1.3M2016
Department Of Agriculture TennesseeNashville, Davidson County$1.2M2025

Source: USAspending.gov. Past awards show who this program funds; they don't guarantee future awards.

About the program (93.103)

Food and Drug Administration Research — General Grant Funding

How applications are judged

Applicants should review the individual Funding Opportunity Announcement (FOA) issued under this CFDA program to see the specific evaluation criteria that applies.

Matching requirements

This program has no statutory formula. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.

Examples of funded projects

Not Applicable.

Program listing on SAM.gov

Something wrong with this listing? Tell us
What's wrong?